Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years

Movement Disorders

Volumn 26, Issue 12, 2011, Pages 2196-2200

  Goetz, Christopher G ^a   Stebbins, Glenn T ^a   Ouyang, Bichun ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dopaminergic therapy; Hallucinations; Longitudinal data; Parkinson's disease

Indexed keywords

AGED; ARTICLE; AUDITORY HALLUCINATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NONVISUAL HALLUCINATION; OLFACTORY HALLUCINATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TACTILE HALLUCINATION; VISUAL HALLUCINATION;

AGED; DISEASE PROGRESSION; FEMALE; HALLUCINATIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARKINSON DISEASE; TIME FACTORS;

EID: 80055089983     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23835     Document Type: Article

References (15)

1. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol. 1970; 23: 193-200.
2. Goetz CG, Ouyang B, Negron A, Stebbins GT. Hallucinations and sleep disorders in Parkinson's disease: ten-year prospective longitudinal study. Neurology. 2010; 75: 1773-1779.
3. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001; 57: 2078-2082.
4. Fahn S, Elton RL, UPDRS program members. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987: 153-163.
5. Diggle PJ, Liang K-Y, Zeger SL. Analysis of Longitudinal Data. Oxford, UK: Oxford University Press; 1994.
6. Goetz CG. Hallucinations in Parkinson's disease: the clinical syndrome. In: Stern GM, ed Advances in Neurology: Parkinson's Disease. Vol. 80. Philadelphia: Lippincott Williams & Wilkins; 1999: 419-423.
7. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson's disease. Arch Neurol. 1996; 53: 1265- 1268.
8. Fenelon G, Thobois S, Bonnet AM, Broussolle E, Tison F. Tactile hallucinations in Parkinson's disease. J Neurol. 2002; 249: 1699- 1703.
9. Goetz CG, Wuu J, Curgian L, Leurgans S. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006; 21: 267- 270.
10. Llebaria G, Pagonabarraga J, Martínez-Corral M, et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov Disord. 2010; 25: 2785-2791.
11. Mamikonyan E, Moberg PJ, Siderowf A, et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord. 2009; 15: 226-231.
12. Goetz CG, Fan W, Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008; 23: 1541-1545.
13. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in Parkinson's disease with hallucinations: an fMRI study. Neurology. 2004; 63: 1409-1416.
14. Mahowald MW, Schenck CH. The importance of longitudinal data on Parkinson's disease, hallucinations, and dream-enacting behaviors. Neurology. 2010; 75: 1762-1763.
15. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23: 2129-2170.